After Xtandi, Will Government Ever Seek March-In Rights Over Drug Pricing?

 
• By Brenda Sandburg

Market availability of Xtandi, not its cost, is the issue, NIH says in denying petition for government to invoke march-in rights to patents on the prostate cancer drug. But Biden administration makes two other same-day moves that could leave march-in advocates with some hope.

Xtandi march in
NIH rejects petition seeking march-in rights to prostate cancer drug patents • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from Pricing Debate

More from Market Access